Hadassah

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

Tuesday, Jan 10 2017

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

The drug, called MM-II, has been commercialized through Moebius Medical, a biotech start-up at Hadasit, Hadassah's technology transfer company, together with the Hebrew University's Yissum and the Technion's T3. In December, Moebius signed an exclusive worldwide licensing agreement with pharmaceutical giant Sun Pharmaceutical Industries Ltd. of India to further develop MM-II. Having completed the first clinical study at Hadassah--a randomized, controlled, double-blinded study with mild to moderate symptomatic knee osteoarthritis  patients--Moebius Medical reports that ”the product has demonstrated fast onset of action, potentially better efficacy, and comparable safety for alleviating osteoarthritis pain when compared to Hyaluronic Acid injection (the standard treatment).” MM-II leverages the physical properties of liposomes (small vesicles that deliver drugs into the tissues) to lubricate arthritic knee joints, thereby reducing friction and wear which, in turn, leads to join pain reduction. Results were presented before the American Academy of Orthopedic Surgeons, Osteoarthritis Research Society International, and the American College of Rheumatology.

How did discovering a solution for locked jaw lead to MM-II? Hadassah’s Prof Dorit Nitzan, a senior surgeon and researcher in Oral and Maxillofacial Surgery, explains:

“Closed locked jaw used to be treated surgically, with the aim of correcting the disc position. We discovered quite surprisingly that arthrocentesis (removing fluid from the joint to relieve the pressure) released the lock. Since arthrocentesis does not change the disc position, we were left with a riddle, not understanding what causes severe closed lock to be immediately released by such an innocuous procedure. The answer, we realized, could be found in the field of mechanical physics. But I didn't know enough physics to work it out. Then, a 15-year-old patient from Haifa came in for treatment of locked jaw. Her father, Prof. Izhak Etsion, wondered if we understood what exactly caused the lock. I told him we were looking for the expert to help us understand the mechanism. He looked at me and said, ‘I am that person.’ ”

Prof. Nitzan went to study with Prof. Etsion at the Technion to understand the role of friction, joint wear, and lubrication from the perspective of mechanical physics. She relates: “We came up with an explanation of the relationship between the adherence forces that lead to locked jaw--what we called 'the anchored disc phenomenon'--and arthrocentesis. This led us to understand the importance of lubrication for synovial joint health.”

The next step was to produce the product that would enhance movement. Prof. Nitzan turned to an expert in liposomes--Prof. Yechezkel 'Chezy' Barenholz, a professor of biochemistry at Hebrew University. His team included Dr. Avi Schroeder, today a professor at the Technion, and, together, they created MM-II, a liposomal, non-opioid lubricant, effective for all synovial joints.

“Think of the bio-material, the liposome we invented, as a liquid with tiny ball bearings which serves as a lubricant for joints,” says Dr. Schroeder. "We were proud of finding a relief for millions of people who suffer from osteoarthritis pain.”

Moshe Weinstein, Chief Executive Officer of Moebius Medical, notes: “The fact that our novel technology was conceived in Israel and developed within the RAD Biomed Accelerator, confirms the unique quality of the country’s biotechnology ecosystem. In fact, our technology was born from the multidisciplinary cooperation among leading professors from three of Israel’s most prestigious research institutions: Prof. Yechezkel Barenholz of the Hebrew University, Prof. Izhak Etsion of the Technion Israel Institute of Technology, and Prof. Dorit Nitzan of the Hadassah Medical Organization.”

Moebius was founded in 2008 within the RAD Biomed Accelerator to develop products based on a patent-protected technology exclusively licensed from the technology transfer arms of Hadassah (Hadasit), the Hebrew University (Yissum), and the Technion’s Israel Institute (T3).

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Related Stories

alt_text

Wednesday, Dec 2 2020

Hadassah Opens Follow-Up Clinic for Recovered COVID-19 Patients

In response to the large number of COVID-19 patients suffering from lingering health issues long after they recover from the virus, Hadassah Hospital Ein Kerem has opened a multidisciplinary clinic at its Pulmonary Institute to monitor and assess their physical and psychological symptoms.

READ MORE ›
alt_text

Tuesday, Dec 1 2020

One in 200,000: Identical Triplets Born at Hadassah Hospital Mount Scopus

Last year, Tamar gave birth to a stillborn baby. When she became pregnant again, she initially didn’t rush to have an ultrasound because of the pandemic. But she wanted to make sure there was a heartbeat, and so she went to Hadassah Hospital Mount Scopus for that ultrasound. There were three heartbeats—belonging to three identical babies!

READ MORE ›
alt_text

Tuesday, Dec 1 2020

Hadassah Completes Phase I Trial With Israeli-Made COVID-19 Vaccine

Phase I of the first clinical trial with Brilife, the COVID-19 vaccine developed by the Israel Institute for Biological Research, was completed at Hadassah Hospital Ein Kerem on November 26, when the 40th participant received the final dose.

READ MORE ›
alt_text

Tuesday, Nov 24 2020

[Hadassah On Call Podcast] COVID's Long-Term Health Impact, an Insider's Perspective

It's no longer enough to find a COVID-19 cure. Each day, we're discovering long-term complications for those who have recovered from the virus.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

More ›

Show More